• Approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed.
• Nanox.AI has signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, with minimum annual license commitments built into the deal.
• A separate optimization project with Intel demonstrates a path for Nanox.AI’s imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud.

A CT scan ordered to answer one clinical question may capture additional anatomical information beyond the original indication. In certain cases, routine CT imaging can include information related to the spine, coronary arteries, liver and other areas, creating an opportunity to support clinical evaluation of findings that may otherwise go unnoticed.

Vertebral fragility fractures illustrate that opportunity. The National Osteoporosis Guideline Group estimates that approximately 549,000 new fragility fractures occur annually in the UK, including roughly 86,000 vertebral fractures. NICE has also stated that most vertebral fragility fractures remain undiagnosed, highlighting the potential value of identifying these findings from scans that have already been performed.

Nano-X Imaging Ltd. (NASDAQ: NNOX) is targeting that gap through Nanox.AI, its medical imaging analytics subsidiary. Two announcements this month advance the same strategy from different directions: one expands the commercial pathway for its bone-health software, while the other addresses how its AI can be deployed within healthcare infrastructure.

Clinical Value from Scans Already Performed

Nanox.AI solutions analyze routine medical CT scans to help identify patients with findings correlated with chronic conditions in areas including cardiac, liver and bone health. Nanox.AI bone solution (“HealthOST”) is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans.

HealthOST is an AI-enabled image processing software that provides qualitative and quantitative analysis of the spine from CT images to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine, such as osteoporosis. The software provides vertebral labeling, vertebral height-loss measurements and vertebral bone-attenuation measurements.

Because eligible CT scans analyzed by HealthOST are performed for other clinical indications, no additional imaging, radiation or patient time is required, enabling opportunistic assessment from routine CT scans. HealthOST is integrated with existing picture archiving and communication systems (“PACS”) and can support timely and appropriate preventive care.

A UK Channel for the Bone Solution

On August 18, Nanox.AI entered a reseller agreement with Vertec Scientific Ltd., granting the company an exclusive license to market and resell HealthOST in the United Kingdom for an initial three-year term, subject to minimum annual license commitments.

Vertec is a UK-based provider of DXA and bone-health solutions, serving hospitals, clinics and healthcare providers across the UK. First established in Berkshire in 1979, Vertec has built nearly five decades of experience as one of the UK’s leading DXA suppliers, supported by nationwide, OEM-authorized engineering coverage and a team of clinically trained applications and product specialists. Its established presence in the bone-health market may provide a specialized commercial channel for HealthOST in the UK.

In November 2025, the National Institute for Health and Care Excellence (“NICE”) included HealthOST, as well as HealthVCF, among five AI technologies recommended as options to aid the opportunistic detection of vertebral fragility fractures in the NHS while further evidence is generated.

Moving Inference Inside the Hospital

Nanox.AI’s second August announcement addressed another potential adoption consideration: where AI processing takes place.

The company optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. The optimized framework ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise AI processing in medical imaging environments.

For healthcare organizations, this type of deployment may support local inference at the edge, help reduce dependence on cloud connectivity and enable deployment models aligned with hospital infrastructure requirements.

Nanox.AI’s technology has also been featured in Intel’s published partner resources as an example of a solution built with Intel technology.

Building the AI Business

Nanox.AI is one component of Nanox’s broader integrated, end-to-end medical imaging and healthcare services platform, which includes Nanox.ARC, Nanox.CLOUD, Nanox.MARKETPLACE, USARAD Holdings and Nanox Health IT.

Nanox generated $4.2 million in revenue in the second quarter of 2026, compared with $3.0 million in the second quarter of 2025. AI and Software Solutions contributed $1.0 million in revenue during the quarter, including $0.9 million generated by Nanox Health IT.

In its September 2026 business update, the company cited continued commercial and clinical momentum for Nanox.AI, including the Vertec Scientific reseller agreement and five new pilot programs

Against that backdrop, the two August developments are relevant to Nanox.AI’s commercial and deployment strategy. The Vertec agreement provides a specialized channel for HealthOST in the UK, while the Intel work demonstrates an approach for running Nanox.AI technology within healthcare environments.

Together, the developments reflect Nanox.AI’s focus on helping healthcare organizations derive additional clinical value from scans that have already been performed.

For more information, visit the company’s website at https://www.nanox.vision.

NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX

• TruGolf’s pending acquisition of Polymath is intended to combine an established Nasdaq-listed technology company with institutional-grade infrastructure for tokenized real-world assets.
• Polymath reported more than $132 million in tokenized assets issued, more than 65 active issuers, and over 50 ecosystem partners as of December 31, 2025.
• Polymath’s vertically integrated infrastructure spans regulated asset issuance and administration, a purpose-built Layer-1 blockchain, confidential settlement, and protocol staking capabilities.
• Polymath reported $4.2 million in 2025 revenue and more than $1 billion in backlog expected to convert within 12 months, with the latter representing identified opportunities rather than guaranteed future revenue.
• TruGolf operates an established commercial golf technology business that generated $5.0 million in revenue during the first quarter of 2026, providing an existing revenue base alongside the company’s planned expansion into tokenized financial infrastructure.

TruGolf Holdings (NASDAQ: TRUG) is a technology company further cementing its leadership in the technology sector by advancing a strategic expansion into digital asset infrastructure through its pending acquisition of Polymath Research Inc., a developer of enterprise-grade infrastructure for regulated digital securities and tokenized real-world assets. Announced in August 2026, the proposed combination is intended to unite Polymath’s tokenization platform with TruGolf’s established, revenue-generating golf technology business under a single Nasdaq-listed company.

Polymath develops technology supporting the issuance, settlement, and lifecycle management of institutionally compliant tokenized financial instruments. Its vertically integrated infrastructure is designed to support regulated real-world assets across private and institutional markets. Polymath reported $4.2 million in 2025 revenue and has established a global ecosystem spanning issuers, financial institutions, and technology partners.

Following completion of the acquisition, TruGolf intends to operate as a holistic digitization company with two complementary lines of business, pairing Polymath’s institutional financial infrastructure with TruGolf’s longstanding virtual golf operations. TruGolf will continue developing its golf simulation software and hardware, connected golf experiences, and TruGolf Links franchise model while pursuing greater operating efficiency and strategic global partnerships through and beyond Polymath.

The company is headquartered in Centerville, Utah.

Tokenization Infrastructure

Polymath provides infrastructure designed to bring regulated real-world assets onto blockchain-based capital markets. Its proprietary technology supports creating and administering digital securities while incorporating identity, compliance, settlement, and confidentiality capabilities into the fabric of tokenized assets.

The Polymath Capital Platform supports the issuance and administration of regulated assets, and its Layer-1 blockchain, Polymesh, provides infrastructure purpose-built for regulated financial instruments. The technology stack also includes Confidential Assets, which leverage zero-knowledge proofs to enable private, compliant settlement, as well as protocol staking and treasury capabilities.

As of December 31, 2025, Polymath reported having issued more than $132 million in tokenized assets, more than 65 active issuers, over 50 ecosystem partners, and a backlog exceeding $1 billion expected to convert within 12 months. The company notes that its backlog consists of identified opportunities at various stages and does not guarantee future revenue.

Polymath has also identified approximately $2.1 billion in tangible potential opportunities across commercial real estate, energy, mining, entertainment, technology, private companies and financial institutions. Its infrastructure is designed to support tokenized representations of assets including real estate equity and debt, private investments, intellectual property, commodities and other regulated financial instruments.

Golf Technology

TruGolf operates an established golf technology business spanning simulation software, hardware and off-course golf experiences. The business generated $5.0 million in revenue in the first quarter of 2026, primarily from golf simulator sales and software contracts.

The company’s technology portfolio includes E6 CONNECT simulation and esports software, E6 APEX, APOGEE launch-monitor technology, and TruGolf RANGE indoor driving-range systems. TruGolf reports that its technology has captured and analyzed more than 75 million player shots.

TruGolf is also expanding the business through its TruGolf Links franchise model among additional distribution channels. The first flagship TruGolf Links franchise opened in Cherry Hill, New Jersey, in July 2026, combining the company’s simulator technology with dining, entertainment, and hospitality. TruGolf and Polymath are exploring developing tokenized equipment-financing and fractional-ownership initiatives for qualified franchise candidates, subject to completion of the acquisition.

Market Opportunity

Tokenization is designed to bring programmable compliance, digital settlement and continuous-market capabilities to traditionally administered financial assets. TruGolf and Polymath identify more than $400 trillion in global financial assets as the addressable base for tokenization, with real estate, private funds, and credit among the principal near-term real-world asset categories.

The companies’ investor presentation notes that tokenized real-world assets could grow from approximately $0.6 trillion in 2025 to $1.6 trillion in 2027, $4.6 trillion in 2029, $9.4 trillion in 2031 and $18.9 trillion in 2033.

TruGolf also participates in the expanding off-course golf market. Company-provided market data shows U.S. golf participation is set to increase from 30.1 million in 2014 to 47.2 million in 2024, while off-course-only participation grew 93% from 2019 to 2024. The U.S. driving-range market totaled $23.3 billion in 2024.

Leadership Team

Brenner Adams, Chairman and Interim Chief Executive Officer, was appointed Interim CEO in September 2026 and also serves as Chairman of TruGolf’s board. He previously served as TruGolf’s Chief Growth Officer and has held executive positions with The Food Truck League, Med USA, and The LINK Group. Earlier in his career, Mr. Adams served as Global Brand Director for Burton Snowboards and worked in business development involving Xbox and Take-Two. He holds a B.S. in Economics and an MBA from the University of Utah.

TruGolf is currently conducting an executive search for a long-term chief executive officer while progressing toward completion of the Polymath acquisition. The leadership structure of the combined company is expected to be further defined as the transaction advances.

NOTE TO INVESTORS: The latest news and updates relating to TRUG are available in the company’s newsroom at https://ibn.fm/TRUG

Date: October 5-7, 2026

Venue: New York City

Stocktwits brings the Stocktoberfest gathering to New York City from October 5–7, 2026. This multi-day experience brings traders, investors, public company executives, financial professionals, and content creators together in a shared, interactive forum.

The event offers different pass options, including the Full Experience Pass.

Stocktoberfest 2026 Full Experience Pass:

• 2.5 days of full event access
• Tennis or pickleball at Century Country Club
• Exclusive NYC activations reserved for attendees
• Curated finance & technology programming
• Tuesday Dinner & Comedy Club access
• Wednesday programming at City Winery

The Full Experience Pass covers participation across two and a half days, combining the core Stocktoberfest conference at the City Winery with Century Country Club activities and private New York City events. The pass also includes Tuesday dinner & Comedy Club access.

The core Wednesday full-day program at City Winery New York City begins with breakfast followed by a full day of panels and fireside chats. Topics announced for the conference include:

• Agentic trading and investing
• Changing role of data and sentiment in brokerage
• Investor relations in the age of artificial intelligence

Topics also include shareholder strategies for emerging technology and small-cap companies, as well as leveraged and inverse ETFs, private markets, and the growing role of retail-investor sentiment.

The event is expected to bring together over 300 attendees and more than 30 speakers. The announced guest list includes Stocktwits Founder and CEO Howard Lindzon, Barry Ritholtz of Ritholtz Wealth Management, Anthony Denier of Webull, Ted Seides of Capital Allocators, executives from Nasdaq Private Markets, and financial-media figures.

To learn more, including additional package option details, please visit https://ibn.fm/2SeZF.

• Orthopedic practice is moving away from a model that manages knee pain until the joint fails, to early structural intervention – a shift that raises the bar for what a cartilage repair product has to deliver.
• Regentis’ GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage, with Phase II data showing approximately 100% greater KOOS improvement than microfracture at two years.
• With CE Mark approval in Europe, pivotal U.S. trial enrollment targeted for completion by approximately year end 2026, and platform work extending toward moderate osteoarthritis, the company is aligned with where the treatment methods are heading.

For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with their own tradeoffs in durability, complexity, and cost. That balance is shifting.

Cartilage defects are increasingly recognized not as isolated injuries but as the starting point of a progressive degenerative cascade. Osteoarthritis now affects nearly 600 million people worldwide, with the knee the most involved joint, according to an IHME study. In response, clinicians are intervening earlier and treating the knee as a structure worth preserving rather than merely a source of pain to be managed.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel implant for focal knee cartilage defects, in a market that is redefining what successful treatment looks like.

Two Forces Reshaping Knee Cartilage Care

Two developments are helping move structural repair up the treatment ladder.

The first is diagnostic. Specialized MRI sequences and high-resolution ultrasound can identify matrix damage, low-grade synovitis, and proteoglycan loss before those changes become visible on a standard X-ray, giving clinicians a clearer picture of structural deterioration earlier in the disease process.

The second is durability data on existing options. Microfracture remains the first-line cartilage procedure mostly for small defects because it is simple, familiar, and inexpensive, but it produces fibrocartilage rich in Type I collagen, and that tissue is prone to breaking down in less than two years. Cell-based procedures generate more durable hyaline-like tissue, though they require a first surgery, weeks of laboratory expansion, and a second surgery, with all-in costs per case that published estimates place in the approximately $45,000 e.

That leaves a market gap between a procedure that is easy to perform but temporary in efficacy and one that is more durable but costly and cumbersome to deliver.

A Matrix Built Around Controlled Resorption

GelrinC is composed of polyethylene glycol and denatured fibrinogen. It is delivered into the defect as a liquid, conforms to the shape of the lesion, and is cured into a solid matrix implant with ultraviolet light. The design intent is what distinguishes it: the implant is engineered to erode at a rate synchronized with the progressive creation of new cartilage tissue in the defect, so the matrix implant recedes, shrinking in size as new tissue forms.

The procedure takes roughly 10 minutes, can be performed using open or minimally invasive techniques, and requires no cell harvesting or return visit to the operating room.

Durability as the Endpoint That Matters

If the treatment goal is structural preservation above and beyond symptom control, multi-year outcomes become the relevant measure.

In a Phase II study of 56 patients across Northern Europe and Israel, GelrinC met its primary endpoints at 24 months, with the company reporting approximately 100% greater improvement in overall KOOS scores than microfracture. No serious adverse events were reported. Patients were followed for up to five years. The company also used MOCART, a nine-part MRI scoring system for cartilage repair tissue, as a predefined endpoint, reporting a mean score of 88.8 out of 100 at 24 months, consistent with near-complete structural repair.

Extending Toward Early Osteoarthritis

The same logic points beyond focal defects. Regentis has described earlier-stage formulations built on the Gelrin platform, including a GelrinP paste form for smaller joints such as the ankle, wrist, and elbow, and injectable thermo-responsive gel targeted at moderate osteoarthritis. Both remain preclinical, supported by animal studies.

In the near term, the company is working through a pivotal FDA trial under an Investigational Device Exemption, using a single-arm design with historical microfracture controls. Enrollment is targeted at 80 patients, with more than half recruited and treated, completion expected by approximately year end 2026, and PMA submission slated to begin at the end of 2027. European commercialization efforts are underway with CE Mark approval having already been achieved.

Whether GelrinC becomes part of the new standard depends on US trial results and regulatory clearance. Although the direction of orthopedic practice, toward earlier intervention and durable tissue restoration, is the environment the product was built for.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

Please see full terms of use and disclaimers on the IBN website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• New analysis noted that gold is “becoming the reserve asset of a new, multipolar world.”
• Resource growth is one of the clearest signals a mining company can offer in that environment, and Lahontan Gold Corp. has delivered exactly that.
• Lahontan is using this expanded resource base to move toward becoming a producer rather than remaining purely an explorer.

Gold miners with expanding resources and open mineralization are drawing fresh attention as investors look for ways to participate in a metal that is being redefined as a strategic reserve asset. That backdrop is exactly where Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) sits, having just grown the resource base at its flagship Santa Fe project in Nevada while continuing to drill targets that extend well beyond its current pit outlines.

The case for gold’s expanding role in the global financial system was laid out in detail in a recent analysis from Sprott Inc., a firm known for its precious metals expertise. The report stated that gold is “becoming the reserve asset of a new, multipolar world,” pointing to central banks diversifying away from dollar-denominated reserves as geopolitical tensions rise. The analysis also noted that gold reserves as a share of total world reserves have climbed sharply since the freezing of Russia’s foreign exchange reserves, reaching a recent high of roughly 34% of total world reserves before settling near 27%.

The analysis described gold as a form of “outside money” that carries no political allegiance, no counterparty risk and cannot be frozen or sanctioned when held domestically. It also cautioned that gold’s shorter-term price swings still respond to the U.S. dollar and interest rate expectations, meaning the metal can see real corrections even within a longer secular bull market.

Resource growth is one of the clearest signals a mining company can offer in that environment, and Lahontan Gold Corp. delivered exactly that last month. On August 17, 2026, the company announced an updated Mineral Resource Estimate (“MRE”) for its Santa Fe Mine showing Indicated Mineral Resources of 1,195,000 gold equivalent ounces and Inferred Mineral Resources of 1,190,000 gold equivalent ounces, a combined increase of 435,000 ounces, or 22%, over its 2024 estimate. The update was built on 1,275 drill holes totaling more than 136,000 meters, including drilling completed by Lahontan itself since 2021.

The growth was not limited to Lahontan’s flagship Santa Fe deposit. Oxide resources at the company’s Slab and York deposits expanded by more than 37%, compared to the 2024 estimate, while combined resources at Santa Fe itself grew by more than 26%, driven in part by the inclusion of deeper sulfide mineralization that had not previously been fully captured. Kimberly Ann, Lahontan founder, CEO and president, noted that the company is “excited by the results of this updated MRE,” particularly the growth in total ounces and the continued expansion of the shallow oxide deposits.

What stands out beyond the raw ounce growth is the open nature of mineralization itself. The updated resource block model shows that gold and silver mineralization extends well beyond the conceptual pit shells used to define the current estimate, generating what the company describes as high-quality targets for additional drilling across multiple zones, including the increasingly important deep sulfide mineralization at Santa Fe. That kind of open-ended geology is precisely what exploration-stage and development-stage investors look for, since it suggests further resource growth is achievable through continued drilling rather than requiring an entirely new discovery.

Lahontan is using this expanded resource base to move toward becoming a producer rather than remaining purely an explorer. The updated estimate will feed into an updated Preliminary Economic Assessment for Santa Fe, evaluating low-cost open-pit mining and heap leach processing alongside a second phase of sulfide processing. Technical consultants based in Reno, Nevada, are advancing mine design and process planning, while the company works through state and federal permitting, with construction targeted for 2027.

Santa Fe itself is not a speculative greenfield project but a past-producing mine, having yielded 359,202 ounces of gold and 702,067 ounces of silver through open-pit, heap-leach operations between 1988 and 1995. That production history, paired with a resource base that has now grown for multiple consecutive updates, gives Lahontan a foundation that combines historical validation with genuine exploration upside.

The company’s broader portfolio adds further optionality. Beyond Santa Fe, Lahontan controls three additional gold and silver projects across Nevada’s Walker Lane, a geological trend recognized as one of North America’s most prolific gold-producing regions. Among its 2026 objectives, the company is targeting a maiden resource estimate at its satellite West Santa Fe project by year-end, alongside continued exploration drilling aimed at expanding known mineralization across its landholdings.

Taken together, a growing resource base, mineralization that remains open in multiple directions and a defined path toward production could place Lahontan Gold Corp. among the Nevada-focused developers best positioned to benefit if gold’s structural repositioning as a global reserve asset continues.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

PAID ADVERTISEMENT. This article is a paid advertisement for BOXABL Inc. (Nasdaq: BXBL), distributed by NetworkNewsWire (“NNW”), a division of InvestorBrandNetwork (“IBN”). IBN has been compensated for advertising and digital media services related to BOXABL Inc. Readers should review the full disclaimer at the foot of this article before making any investment decision.

• The company has unveiled a Server Pod design concept aimed at demonstrating how its factory could be used to manufacture custom enclosures for AI and cloud-computing infrastructure.
• BOXABL is not currently manufacturing or selling Server Pods; the concept is intended to attract data center developers and equipment companies for potential custom projects.
• JLL projects approximately 100 gigawatts of new global data center capacity could come online between 2026 and 2030, requiring as much as $3 trillion in investment.
• BOXABL believes factory assembly could address some of the industry’s construction constraints, particularly rising costs and lengthy deployment timelines.
• The company’s conceptual designs range from compact 10-foot and 20-foot units to larger 40-foot configurations and a proposed 2,500-square-foot “Server Tron.”
• The initiative gives BOXABL a potential avenue to apply its manufacturing infrastructure beyond its core housing business and into a rapidly expanding AI infrastructure market.

BOXABL (NASDAQ: BXBL), an innovative technology company transforming the housing market with its modular building systems, is testing the boundaries of its factory-built construction model with a new concept aimed at one of the fastest-growing infrastructure markets: data centers. The company unveiled its Server Pod concept on August 20, presenting a series of factory-assembled enclosure designs intended to house AI and cloud-computing infrastructure (https://ibn.fm/SzTtf).

The announcement is not the launch of a new commercial product. BOXABL has not begun manufacturing Server Pods and is not offering them for sale. Instead, the company is using the concept to demonstrate what its existing factory infrastructure could potentially build for data center customers and to invite developers and equipment manufacturers to discuss custom projects.

The timing reflects a significant change taking place in the data center industry. According to JLL’s 2026 Global Data Center Market Outlook, global data center capacity is expected to expand by roughly 100 gigawatts between 2026 and 2030, nearly doubling existing capacity. JLL estimates that accommodating this expansion could require approximately $3 trillion in investment, including real estate development and spending on servers, GPUs and networking equipment.

Construction itself is becoming more expensive. JLL reports that data center construction costs have increased at approximately a 7% compound annual growth rate since 2020. At the same time, access to electricity has become a major constraint. Developers in some primary markets face grid-connection waiting periods exceeding four years, making speed to power an increasingly important consideration when selecting sites.

For data center operators, therefore, the challenge is not simply securing land and installing computing equipment. The physical infrastructure needed to house that equipment has to be delivered quickly enough to keep pace with demand.

That is where BOXABL’s manufacturing model enters the discussion. The company’s core proposition is to move construction activity from a conventional job site into a controlled factory environment. Rather than assembling an entire structure from raw materials at its final location, BOXABL manufactures building components in a production setting before transporting them to the site.

The Server Pod concept extends that philosophy to compute infrastructure. BOXABL has illustrated several conceptual configurations, ranging from a 10-foot enclosure envisioned around eight racks to a 40-foot configuration with 36 racks. A larger 2,500-square-foot concept, called “Server Tron,” illustrates how the same factory-built approach could potentially scale to larger deployments.

These are design-study targets, not specifications for a manufactured product. Any actual deployment would require project-specific engineering, equipment selection, permitting and validation of local conditions.

The proposed architecture also reflects the specialized requirements of data centers. The concepts contemplate insulated building envelopes, filtered-air and liquid-cooling approaches, pre-installed racks and factory-level preparation intended to reduce the amount of work required after delivery. Units could potentially be transported on structural pallet frames and positioned on prepared sites. In practice, the final configuration would depend on the customer’s computing hardware, power requirements, cooling system, local building codes and site conditions.

The opportunity is particularly relevant as AI workloads continue to drive demand for computing capacity. JLL estimates that AI accounted for approximately a quarter of data center workloads in 2025. The research firm expects the mix of workloads to evolve as AI inference becomes increasingly important, potentially pushing some computing requirements closer to end users and regional markets rather than keeping all workloads concentrated in the largest centralized facilities. That could increase demand for distributed computing infrastructure.

For BOXABL, a factory-based manufacturing process could potentially be useful in that environment because repeatable structures can be produced away from congested construction sites and delivered to locations where additional computing capacity is required.

The company is therefore seeking conversations with data center developers, hyperscalers, colocation providers and equipment manufacturers. Any commercial opportunity would require a separate agreement under which BOXABL would design and manufacture a structure according to a customer’s requirements.

The initiative also illustrates how BOXABL is attempting to broaden the potential application of its manufacturing infrastructure while retaining its central focus on housing.

BOXABL was established around the idea that housing could benefit from manufacturing-style production. Its best-known product, the Casita, is a 361-square-foot modular unit designed to be manufactured in a factory and deployed on site. The company has positioned that model as an alternative to conventional site-built construction, with an emphasis on production efficiency and scalability.

For more information, visit the company’s website at www.Boxabl.com.

NOTE TO INVESTORS: The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL

Cautionary Note Regarding the Business Combination and Capital Structure. BOXABL Inc. became a publicly traded company through a business combination with FG Merger II Corp., a special purpose acquisition company, completed in July 2026, with the shares beginning trading on the Nasdaq Stock Market under the symbol BXBL on July 20, 2026. Companies that become public through special purpose acquisition transactions may be subject to risks including share price volatility, dilution, limited operating history as a public company, and redemption-related capital reductions. In July 2026 the Company filed a universal mixed shelf registration statement that would permit it to offer up to $500,000,000 of securities over time; any such issuance would be dilutive to existing holders. References to capital raised since inception and to the number of investors are as disclosed by the Company. Readers should review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov, including its periodic reports, in full.

Cautionary Note Regarding Forward-Looking Statements. This publication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including projections of market opportunity and market share, estimates of customer adoption, projections of development and commercialization costs and timelines, expectations regarding the Company’s ability to execute its business model, the deployment of the Casita, the development and potential production of the Baby Box and of stackable and connectable modules, the pursuit of additional state regulatory approvals, expectations concerning relationships with customers, developers, strategic partners, suppliers, governments and regulatory bodies, and the potential for future projects. Such statements are generally identified by words such as “plan”, “project”, “will”, “estimate”, “intend”, “expect”, “believe”, “target”, “continue”, “could”, “may”, “might”, “possible”, “potential” or “predict”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual circumstances, events, or results to differ materially, including manufacturing, supply chain, permitting, regulatory, financing, dilution, listing, competitive and market risks, and other risks identified in the Company’s filings with the Securities and Exchange Commission. Do not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date above and IBN undertakes no obligation to update them.

Full Disclaimer. NetworkNewsWire (“NNW”) is a division of InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company. IBN has been compensated for advertising and digital media services for BOXABL Inc. This publication is for informational purposes only and is not, and should not be construed as, a research report, investment advice, or a recommendation to buy or sell any security. The information contained herein is believed to be reliable but no guarantee can be made as to its accuracy or completeness. Neither IBN nor NNW is registered as an investment adviser or broker-dealer. Readers should review BOXABL Inc.’s filings with the U.S. Securities and Exchange Commission and consult with a licensed financial advisor before making any investment decision. Please see the full terms of use and disclaimers applicable to all content provided by IBN, wherever published or re-published, at https://IBN.fm/Disclaimer.

• Utility power for large data centers can take years to secure, and demand continues to rise faster than the grid can expand to meet it.
• Atlas One is Azio AI Holdings’ answer to that pressure; the project spans more than 548 acres in south Texas and is engineered for up to 500 megawatts of planned behind-the-meter power capacity.
• The name Atlas One reflects a broader naming convention the company plans to use going forward, tying separate land, power and fiber updates together under one project.

Building an AI data center is no longer just about buying enough graphical processing units (“GPUs”); rather, it is about finding enough electricity to run them. Azio AI Holdings (NASDAQ: AZIO) is committed to addressing that challenge, and just announced its Atlas One project, a South Texas compute campus designed around power the company generates itself.

Utility power for large data centers can take years to secure, and demand continues to rise faster than the grid can expand to meet it. Goldman Sachs Research projects U.S. data center power demand will climb from 31 gigawatts in 2025 to 66 gigawatts in 2027. That gap has pushed developers toward on-site power generation as a way to control their own construction timelines.

Atlas One is Azio AI Holdings’ answer to that pressure. The project spans more than 548 acres in south Texas and is engineered for up to 500 megawatts of planned behind-the-meter power capacity. The company has already secured approximately 11 megawatts of behind-the-meter natural gas generation and supporting electrical infrastructure at the site. 

About 6 megawatts of that secured power has been already been activated to run compute infrastructure, the company has reported. That activated 6 megawatts has run a Bitcoin mining workload as an initial test of the power system, achieving roughly 97.8% uptime, with the company noting that the figure reflects a mining workload rather than a service-level commitment for AI or high-performance computing customers.

Azio AI Holdings has also committed approximately $2.4 million to a master services agreement with AT&T for dedicated enterprise fiber at the site, part of the connectivity buildout supporting the project. Natural gas pipeline and metering infrastructure is under development alongside it, the company said.

The name Atlas One reflects a broader naming convention the company plans to use going forward. Azio AI Holdings said future sites will be named Atlas Two, Atlas Three and so on as they are announced, tying separate land, power and fiber updates together under one project. “We have been building Atlas One for months,” stated Azio AI CEO Chris Young. “Naming it is how we make clear to the market that the land, the power, the fiber and the compute are one project on one site, not a collection of separate announcements.”

Beyond Atlas One, Azio AI Holdings’ broader business includes GPU hardware sales and hosting agreements, though the company said those are structured as separate commercial arrangements. That includes an agreement to sell up to 512 NVIDIA HGX B300 GPU systems to Power Champion Investment Limited, worth an estimated $307 million. That agreement supplements previous hosting agreements with Power Champion, which the company said reflects the type of hosting demand Atlas One is being built to serve. 

Azio AI Holdings’ near-term priorities include finishing infrastructure for its initial 11 megawatt phase, advancing natural gas pipeline work and completing fiber connectivity under the AT&T agreement. The company plans to pursue customer hosting and offtake agreements as that infrastructure comes online; the company noted that realizing its full 500 megawatt vision will require additional generation, equipment, permitting, financing and customer commitments that are not yet in place. 

Azio AI Holdings framed Atlas One as connecting two sides of its business — GPU hardware sales and physical hosting infrastructure — rather than treating them as separate ventures. Company officials believe that hardware relationships, such as the one with Power Champion, may eventually create demand for the hosting capacity Atlas One is being built to provide.

For now, Atlas One is a construction and permitting story, working toward becoming an operating one. Its progress over the coming months, particularly as the initial 11 megawatt phase gets built out and contracted, will show whether Azio AI Holdings can turn a power-first strategy into paying AI customers.

For more information, visit www.AzioAI.ai.

NOTE TO INVESTORS: The latest news and updates relating to AZIO are available in the company’s newsroom at https://ibn.fm/AZIO

Date: October 7, 2026

Venue: City Winery, New York City

In its second year, leading investor social platform Stocktwits’ Stocktoberfest gathering is moving to the center of the financial universe — New York City — for its gathering of traders, investors, public company executives, financial professionals, and content creators, to generate real conversations that move markets and build lasting relationships.

On Oct. 7, Stocktwits will sponsor programming of panels and fireside chats at the City Winery designed to address everything from macro trends to the future of retail investing with market leaders, traders and executives.

Stocktwits is offering a one-day pass to the main investor conference, which includes discussions of the following:

• Real historical crowd calls, revealed before the market knew the outcome
• Data, distribution and sentiment — not the trading UI — becoming the next moat
• How AI agents source signal, and the value of community-generated sentiment data
• How companies communicate to both human investors and their AI agents
• Top retail voices on building real communities and trust that algorithms can’t match

The day will begin with a breakfast gathering, followed by the keynote fireside chat with Barry Ritholtz, the co-founder, chairman, and chief investment officer of financial planning and asset management firm Ritholtz Wealth Management LLC, which has more than $9.4 billion in assets under management.

The lineup also features additional fireside chats, including two that focus on market strategies for individual investors and their portfolios:

• Social Arbitrage and the Democratization of Investing
• Private Markets: Getting In Before the Story Is Public

The event also fosters networking opportunities to build connections that will “compound over time,” according to the organizers. The programming is the culmination of Stocktwits’ month-long celebration that brings the spirit of Oktoberfest to the markets with community-driven content, interactive features and live events across newsletters, video shows and social media.

The role of artificial intelligence in the evolving marketplace is a core theme of the gathering. Whether in finance, the crypto markets, options trading, retail investor trends or the development of financial media, AI is expected to be a key player in the years to come.

To learn more, including additional package option details, please visit https://ibn.fm/hesEu.

• The program began with a robotic left internal mammary artery (“LIMA”) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra advanced robotic surgical system from SS Innovations.
• SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025.
• The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines.
• SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery LIMA take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.

“We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region,” the company wrote in a LinkedIn post (https://ibn.fm/TTTdR). “At SS Innovations International, Inc. we remain committed to enabling hospitals and surgical teams across the country to bring advanced, affordable robotic surgery to more patients, in more places.”

The Ahmedabad deployment adds another cardiac program to an installed base that is increasingly being used across specialties and geographies. The announcement comes shortly after SS Innovations reported that 238 SSi Mantra systems had been installed as of September 8, compared with 168 at the end of 2025. That represents a 42% increase in the installed base during the period.

Procedure volumes have grown more rapidly. The company reported 14,103 cumulative multi-specialty procedures using SSi Mantra as of September 8, up from 7,885 at the end of 2025, an increase of 79%. Approximately 1,500 physicians have been trained on the system, which has been used for more than 170 different types of surgical procedures.

The figures provide a measure of the operating base SS Innovations has established in India while the company works to replicate that model internationally. In July, SS Innovations launched a robotic cardiac surgery program at La Fundación Cardiovascular de Colombia in Bucaramanga. The program included Colombia’s first Totally Endoscopic Beating-Heart Bypass Surgery performed using SSi Mantra.

In August, Kings Hospital Colombo installed the first SSi Mantra system in Sri Lanka. The company subsequently reported the country’s first robotic-assisted cardiac surgery using the platform, followed by more than 25 additional robotic procedures during the system’s first three weeks of operation.

With the Sri Lankan installation, SS Innovations said the SSi Mantra’s installed base had reached 12 countries.

The company is also extending the platform into pediatric procedures. On August 14, SSi Mantra and 5-millimeter instruments were used for a robotic pyeloplasty on a 45-day-old infant at Hindusthan Hospital in Coimbatore, India. SS Innovations reported 258 cumulative pediatric robotic surgeries as of August 31.

Telesurgery represents another developing application. As of August 31, the company reported 188 robotic telesurgeries using SSi Mantra. One July procedure connected surgeons at Hospital Internacional de Colombia in Bucaramanga with a patient at Mohak Bariatrics and Robotics in Indore, India, across more than 13,600 miles of fiber-network distance.

In September, SSi Mantra was also used for what the company described as the first telesurgery within the Philippines, connecting Pampanga and Cotabato across approximately 1,710 kilometers.

SS Innovations is positioning SSi Mantra around both advanced surgical capabilities and accessibility. The platform is a modular system with three to five robotic arms, a 3D 4K visualization system and more than 40 types of robotic endo-surgical instruments, according to the company. Its product range also includes the SSi Mudra instrument portfolio and the portable MantrAsana tele-surgeon console.

The next major development area is regulatory expansion. SS Innovations submitted its SSi Mantra 510(k) premarket notification to the U.S. Food and Drug Administration in December 2025. The company now expects the FDA review to be completed by the end of the first quarter of 2027. It also believes the SSi Mantra can obtain European Union CE marking by the end of 2026.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS.
• What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism.
• Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated.

A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS, clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate.

The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that was not possible without FDA clearance.

According to the announcement, the upcoming study will be randomized, double blind and placebo controlled, a design considered the gold standard for testing whether a new drug actually works. Researchers plan to measure efficacy, safety and tolerability in people living with MS, tracking both clinical symptoms and radiological changes in the brain. Site selection and other trial start-up activities are already underway, with patient enrollment expected to begin as soon as possible.

What sets Lucid-MS apart from most existing MS therapies is its mechanism. The compound is designed to protect nerve cells by inhibiting demyelination, the breakdown of the fatty sheath that insulates nerve fibers. This sheath is critical in allowing the brain to communicate effectively with the rest of the body. Most currently approved MS drugs instead work by suppressing or modulating the immune system, an approach that can leave patients vulnerable to infections and other side effects.

Lucid-MS targets an enzyme called peptidyl arginine deiminase 2, or PAD2, which has been implicated in the breakdown of myelin when its activity is increased. In preclinical models, the compound demonstrated the ability to protect the myelin sheath from this type of damage, supporting its potential as a neuroprotective approach in MS. The company notes that the compound also was not found to suppress the immune system, distinguishing its proposed approach from most currently marketed treatments.

Before reaching this milestone, Lucid-MS completed phase 1 clinical trials in healthy human volunteers. Quantum BioPharma reported that the drug showed a favorable safety profile and was well tolerated in that earlier testing, an important precondition for moving into a patient population. The underlying science behind the compound has also been published in peer-reviewed journals, including the Journal of Medicinal Chemistry and the Proceedings of the National Academy of Sciences.

Quantum BioPharma also disclosed its financial position alongside the clinical update. The company reported approximately $10 million in cash, digital assets and liquid investments as of June 30, 2026, providing some runway as it moves into the more resource-intensive phase 2 stage of development.

There is no cure for multiple sclerosis today, and the disease remains a leading cause of neurological disability among young adults. The FDA’s clearance does not guarantee that Lucid-MS will ultimately prove effective or reach the market; all drug candidates that begin clinical trials do not receive final approval. Phase 2 testing exists specifically to answer the question of a drug’s effectiveness and safety, gathering real-world data on how the drug performs against a placebo in an actual patient population.

However, for a company still in the clinical stage of development, an FDA clearance represents significant forward momentum. Investors and patients alike will likely be watching for updates on site activation, enrollment progress and eventual trial data as Quantum BioPharma works to advance a treatment approach it believes is fundamentally different from what is currently available.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM